Business
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results
Conference Call and Webcast March 15 at 8:00 am Eastern Time / 7:00 am Central Time Currently Dosing Patients in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":"\nConference Call and Webcast March 15 at 8:00 am Eastern Time / 7:00 am Central Time\n\n\nCurrently Dosing Patients in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial\n\n\nTeam Expanded with Addition of Chief Medical Officer and Chief Commercial Officer\n\n\nStrong Balance Sheet with $45M Cash, Runway Into 2024\n\n\n MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the year ended December 31, 2021. Management will host a conference call Tuesday, March 15, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and full year financial results.\n\n“Our clinical, regulatory, financial and team building achievements in 2021 have laid a solid foundation for success,” said Rick Pauls, CEO of DiaMedica. “In 2022, our team is focused on executing on our Phase 2/3 ReMEDy2 trial of DM199 in acute ischemic stroke to reach the blinded interim analysis in 2023.”\n\nPivotal Phase 2/3 ReMEDy Trial of DM199 for Acute Ischemic Stroke Initiated & Building Out Hospital Study Site Network\n\nThe Phase 2/3 ReMEDy2 trial is a randomized, double-blind, placebo-controlled Phase 2/3 adaptive trial designed to enroll 350 patients at approximately 75 sites in the United States. Patients enrolled in the study will be treated with either DM199 or placebo within 24 hours of the onset of acute ischemic stroke (AIS) symptoms. The study excludes patients treated with tissue plasminogen activator (tPA) and those with large vessel occlusions. The study population is representative of the approximately 80% of AIS patients who do not have treatment options today, primarily due to the short treatment window of up to 4.5 hours from symptom onset required for administration of tPA.\n\nThe ReMEDy2 trial will evaluate the effects of DM199 on both stroke recoveries post AIS, as measured by the well-established modified Rankin Scale (mRS), and the incidence of AIS recurrence at day 90 as two separate, independent, primary endpoints, with each statistically powered for success. Recurrent strokes represent 25% of all ischemic strokes, often occurring in the first few weeks after an initial stroke, and are typically more...